#Cobertura #CLOC #ScienceLink
Dra. Eva Ciruelos (Eva M Ciruelos)

Organizado por CLOC: Curso Latinoamericano de Oncología Clínica (@cloc_oncologia)

shorturl.at/EFJK2

#GBM #neuroonco We show to you our experience in ketogenic metabolic therapy in patients with recurrenthigh grade glioma athenaeumpub.com/the-effect-of-… EANO SNO Society for Neuro-Oncology Latin America GEINO giuseppe Minniti Lombardi Giuseppe Jan-Michael Werner Angelo Dipasquale Jorge Aponte Monsalve MD. Camilo Vallejo Yepes

Back in business: The SOCCER⚽️ASCO game is back during #ASCO24 .

Monday JUNE 3rd: 6-10 pm CST

See below for location and other matters

Email: [email protected] with your team

OncoAlert

#Cobertura #CLOC #ScienceLink
Dr. Rodolfo Gómez

Organizado por CLOC: Curso Latinoamericano de Oncología Clínica (CLOC: Curso Latinoamericano de Oncología Clínica)

shorturl.at/cDTU3

Registration is open and 16 football teams will be selected!
Registration fee to be paid onsite) 🇦🇷🇧🇷🇫🇷🇺🇸🇨🇴🇦🇺🇯🇵🇨🇳🇪🇸
All people is allowed (different countries, gender, employers, etc (academic/industry)

🔥⚽️🔥 the most funky, friendly, fashioned social event of the oncology community is como back again this year! 🚀🚀 The #ASCO24 football tournament. The latest versions were a lot of fun. 😎 Don't miss it and sign up!🔥
With a rock stars Toni Choueiri, MD and FabriceAndre OncoAlert…

Another MAJOR development in GU Cancers presented at #EAU24 . Nivolumab improves OS in bladder cancer ! This is major. First IO/PD1 to prolong OS in adjuvant urothelial cancer —congrats to the field, the patients, Matt Galsky and all. Major milestone!

OncoAlert joaquim bellmunt…

Congrats LACOG friends for a this climate of excellent and inclusivity in all Latin America Cancer Research ! You set the bar high!

André P. Fay FLoscoMD Andrey Soares et al

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors | FDA fda.gov/drugs/resource…

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

👏👏 Impressive data in this ctDNA - ve cohort of IMvigor011 phIII study! 👉 more biomarkers to better define the high risk population! #EAU24 International Society of Liquid Biopsy OncoAlert

It is really important to see trials evaluating treatment deescalation! Pts not only need better treatments, but also better selection tools!

#Cobertura #CLOC #ScienceLink
Dr. Luis Paz-Ares (Luis Paz-Ares)

Organizado por CLOC: Curso Latinoamericano de Oncología Clínica (@cloc_oncologia)

shorturl.at/eQUW0

What could be the right treatment for papillary #rcc ? Ongoing clinical trials will give an answer.
Now I am proud to present our global experience just published on European Urology Oncology
Thanks to MatteSantoni all ARON Team!
Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Uromigos European Association of Urology (EAU) AIOM SIUrO

#Cobertura #CLOC #ScienceLink
Dr. Luis Paz-Ares (Luis Paz-Ares)

Organizado por CLOC: Curso Latinoamericano de Oncología Clínica (@cloc_oncologia)

shorturl.at/hzAS8

Important study and an unmet medical need in kidney cancer (M1NED)—

Congrats Leonard Appleman ECOG-ACRIN Cancer Research Group and the whole team on this publication in Journal of Clinical Oncology!

OncoAlert ASCO KidneyCAN Kidney Cancer

#Cobertura #CLOC #ScienceLink
Dr. Ricardo Brugés Maya (Ricardo Bruges Maya)

Organizado por el Curso Latinoamericano de Oncología Clínica (CLOC) 2024 (@cloc_oncologia)

shorturl.at/xGP17

#Cobertura #CLOC #ScienceLink
Dr. Ricard Mesía

Organizado por el Curso Latinoamericano de Oncología Clínica (CLOC) 2024 (CLOC: Curso Latinoamericano de Oncología Clínica)

shorturl.at/qrY18

Fascinating “Don’t ever, ever call me a self-made man” - Arnold Schwarzenegger